osimertinib
astrazeneca
['osimertinib']
the dfs hr of 0.23 in resected stage ii/iii remains very impressive. but once osimertinib is stopped after 3y, the curves do seem to be coming closer together. dfs at 2y with osi is 90% and at 3y is 84% but drops to 70% at 4y. are we preventing recurrence or delaying it? #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him